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Abstract
Most of the problems in pain control in end of life care are encountered due to three main syndromes or 
their combinations: neuropathic pain, opioid-induced hyperalgesia and opioid tolerance. In this article, we 
discuss a patient who was no longer responding to opioids and suffering severe pain, while the opioid dose 
was very high and still rising. It may be apparent that the three syndromes have a lot in common and their 
differentiation is not straightforward. However, guidelines can be given for differentiation and a rational 
approach to treatment. 
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Introduction
In palliative care it sometimes happens that pain 
rapidly exacerbates and that even high doses of 
opioids do not provide adequate analgesia. At that 
point, it is important to go back to basics and first 
try to understand the nature of the pain, to put the 
facts in a row and try to interpret the situation us-
ing definitions and evidence. Not infrequently there 
is not much time to do this, as the patient’s suffer-
ing is overwhelming and the pressure on the doctor 
“to do something” is very high. Increasing the dose 
of opioid once more is not usually the answer. In 
cases of severe pain exacerbation, a couple of syn-
dromes should be considered.
First of all, the patient may have a pain that 
does not respond well to opioids. Neuropathic pain 
is a classic example of this and this pain may be 
only partially opioid responsive [1, 2]. This type of 
pain may respond to a certain degree but a further 
increase will not improve analgesia. Secondly, the 
patient may suffer from opioid-induced hyperalgesia 
(OIH), which is a relative newcomer in palliative care 
but is probably more common than we previously 
thought [3, 4]. Opioids, besides their inhibitory ef-
fects on pain transmission, may at the same time 
interact with Toll 4 receptors in the spinal and brain 
glia and induce pain, facilitating an inflammatory 
response [5, 6]. Thus, with this syndrome, the more 
opioids given, the more pain is produced. The third 
syndrome is that of opioid tolerance, when pain 
is still responsive to opioids but the doses to obtain 
this effect are becoming higher and higher [7]. All 
three of these syndromes overlap each other in many 
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ways and may be accompanied by similar adverse 
effects. From the clinical point of view it is essential 
to differentiate these three syndromes, as the treat-
ment of pain in each case is different. 
In this article we try to differentiate these three 
syndromes using a clinical case. We also try to pro-
pose a rational approach to the treatment of each 
one. 
A man (aged 59) was diagnosed a year earlier 
with a poorly differentiated non-small cell lung 
cancer. There were no distant metastases but the 
disease was locally advanced with tumour growth 
in mediastinum. The patient underwent intensive 
radiotherapy which was complicated by myocardial 
infarction. While waiting for funding for erlotinib 
therapy, he experienced severe pain in his back and 
was treated, initially with success, with control-
led-release morphine sulphate 60 mg bd. However, 
in the course of two months the dose of control-
led-release morphine sulphate was increased to 
460 mg bd. Besides this, he was taking 30 mg of oral 
morphine 4–6 times daily, usually with some pain 
relief which persisted for 3–4 hours. Altogether, the 
morphine sulphate dose averaged 1100 mg daily. 
He did not, apparently, develop constipation while 
taking these high doses of morphine. Other medi-
cation consisted of paracetamol 4 g a day and am-
itriptyline 10 mg nocte. The dose of the latter drug 
was kept low because of the history of myocardial 
infarction. With this medication the pain gradually 
became worse. He experienced severe hypersensitiv-
ity to pinprick, especially on his back (Figure 1). He 
was admitted to the ward for a swap from morphine 
to buprenorphine; buprenorphine was started in 
patches at the dose of 70 mg/hour. He was still al-
lowed to use immediate-release morphine sulphate, 
60 mg per dose at that time. Not surprisingly, he 
only used the extra doses of morphine occasionally 
and the amount was decreased later to 30 mg per 
dose. Later the dose of controlled-release morphine 
sulphate was gradually decreased to 90 mg bd. In 
expectation of neuropathic pain being the main 
problem, oxcarbazepine 150 mg bd was added to 
his medication. At this time the patient felt much 
better and asked to go home. His pain was much 
better controlled, but still present. He was dis-
charged with the possibility of using the 30 mg 
extra dose of morphine sulphate when needed 
and was scheduled to be seen in the clinic two 
weeks later. However, for no apparent reason, 
he did not show up until a month later, when he 
was again in severe pain. The dose of controlled-re-
lease morphine sulphate was increased again by the 
general practitioner to 180 mg bd, and the patient 
was using 8 doses of immediate-release morphine 
sulphate 30 mg (total daily dose: 600 mg). Above 
all he started to complain of a local reaction to 
the buprenorphine patches and needed to discon-
tinue them.  After that the morphine dose shot up 
again and the pain became unbearable. He was ad-
mitted once more. On examination he appeared 
relatively well. There was marked hyperalgesia in 
the dermatomes T2–T8, right more than left. There 
was also marked allodynia present on the right side. 
Chest compression from the sides and front-to-rear 
was not painful, suggesting that the pain was not 
due to bony involvement. An abdominal ultrasound 
did not reveal any organ pathology.
At that stage oxcarbazepine was discontinued 
as being completely ineffective. Diclofenac 50 mg 
tds was started and this brought a massive improve-
ment in the pain. This allowed us to decrease further 
the dose of morphine sulphate and he was swapped 
to methadone, allowing morphine sulphate 10 mg 
to be used as a rescue medication.  The dose of 
methadone was titrated up to 50 mg bd. The quality 
of analgesia improved dramatically but the patient 
Figure 1. The area of hyperalgesia (marked with pen) 
is diffuse and does not correspond with distribution 
of any known nerve
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became constipated for the first time and needed 
laxatives.
At this time the patient also started to take er-
lotinib 150 mg od and began to experience a mild 
skin rash because of this drug. Six weeks later a pro-
gression of the tumour was diagnosed and erlotinib 
was discontinued. The patient remained pain free 
using a combination of an increased methadone 
dose of 80 mg bd, diclofenac and occasionally im-
mediate-release oral morphine 10 mg.
Discussion
Our patient suffered from pain that initially re-
sponded to opioids. The distribution of the hyperalge-
sia did not correspond with the potentially damaged 
neurological structures and could not be described 
with dermatomes. The pain gradually increased and 
very high doses of morphine were administered. 
The patient reported that each dose increase gave 
some relief for a short while, which was why the 
dose of morphine increased so swiftly. The patient 
was treated with oxcarbazepine but did not experi-
ence any improvement. While this fact is not strictly 
differentiating, it makes neuropathic pain less prob-
able. Neither did the original pain description suggest 
that there was neuropathic pain before the start of 
the opioid treatment. Was this, therefore, a feature 
of the rapid progression of tolerance or OIH? It is im-
portant in answering this question to know what 
happens after a reduction of an opioid dose. In the 
case of OIH, the pain would improve, while in the case 
of opioid tolerance the pain would become worse. In 
the case of neuropathic dose reduction, this would 
not at first have any effect on the pain, but total 
discontinuation of opioids could induce a worsening 
of the pain. In our patient, a massive reduction in the 
opioid dose resulted in pain improvement; however, 
we were not able to or did not pursue the complete 
discontinuation of opioids. The lack of characteris-
tics of neuropathic pain suggested to us that our 
patient was suffering from OIH.
However, the patient responded swiftly to a dose 
decrease and the introduction of diclofenac, while 
the normal doses of paracetamol were not able to 
change the clinical outcome. Paracetamol may be 
effective in the treatment of hyperalgesia caused by 
low doses of opioids [8] but it appears to be inef-
fective when given with high and very high doses of 
opioids [9]. 
Opioid-induced hyperalgesia differs from opioid 
tolerance in the shift of the dose-response curve in 
two different directions (Figure 2). In opioid toler-
ance the shift is to the right, but there is no specific 
pain facilitation. Tolerance is defined as a state of 
adaptation in which exposure to a drug induc-
es changes that result in a decrease of the drug’s ef-
fects over time. Many processes may contribute to 
this adaptation. Among them, the most important 
seem to be desensitization and the down regulation 
of opioid receptors [10]. On the other hand, OIH 
involves a number of mechanisms that facilitate 
pain, hence the shift of the dose-response curve 
downwards and a decrease in the pain threshold 
[11]. It is believed at the moment that morphine 
and other opioids may have an agonistic effect on 
the TLR4 receptors on the surface of the spinal mi-
croglia. Diverse drugs are able to interact with the 
TLR4 receptor and initiate a pro-inflammatory and 
pro-nociceptive response [5]. Most interesting is that 
morphine-3-glucuronide, a morphine metabolite 
thought to be inactive as it cannot bind to classical 
opioid receptors, is able to interact as an agonist 
of the TLR4 receptor [12]. The active morphine 
metabolite, morphine-6-glucuronide, is devoid of 
this activity [12]. The inflammatory response can be 
inhibited by the effect of NSAIDs; in the case of our 
patient, diclofenac [13, 14].
Figure 2. Tolerance and opioid-induced hyperalgesia 
(OIH) are pharmacologically distinct phenomena that 
share the same net effect on dose requirements. 
Either condition necessitates dose escalation for 
maintaining a certain drug effect. If tolerance is 
expressed, decreased drug potency is reflected by a 
right-shift of the dose versus effect relationship (AC). 
If OIH is expressed, increased pain sensitivity is re-
flected by a downward shift of the dose versus effect 
relationship (AB). Both tolerance and OIH result in 
the decreased effectiveness of a given drug dose (X). 
Modified from [31]
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The treatment of pain in each of the three syn-
dromes is different. In the case of neuropathic pain 
there is not much of a rationale behind treating the 
pain with opioids alone. Opioids should be titrated 
up until a flattening of the dose-response curve 
is obtained [2]. Other drugs, with more specific 
effects on neuropathic pain, should be added, the 
most common being carbamazepine or its congener 
oxcarbazepine [15]. However, carbamazepine may 
inhibit UGT2B7 glucuronyl transferase, thus inhib-
iting the metabolism of morphine to morphine 
glucuronides [16]. Oxcarbazepine, at least in mice, 
increases the anti-nociceptive effect of morphine 
and decreases morphine tolerance [17]. Gabapentin 
and pregabalin are frequently used, besides car-
bamazepine and oxcarbazepine [18–20]. The addi-
tion of NSAIDs is frequently used in the treatment of 
neuropathic pain, although no firm evidence exists to 
support this [21]. 
Opioid-induced hyperalgesia should mainly be 
treated through dose reduction [4] and the addition 
of drugs such as non-steroidal anti-inflammatory 
drugs and/or antagonists of the NMDA receptor, ket-
amine [22]. TLR4 receptors are sensitive to ultra-low 
Table 1. Differential diagnosis of neuropathic pain, opioid-induced hyperalgesia and opioid tolerance
Neuropathic pain Opioid-induced hyperalgesia Tolerance
Definition Pain initiated or caused 
by a primary lesion 
or dysfunction in the 
nervous system. Pain in the 
area of altered sensation
OIH is a paradoxical response 
to an opioid agonist, whereby 
instead of an analgesic  or 
anti-nociceptive effect occurring, 
there is an increase in pain 
perception
Progressive lack of response 
to a drug thus requiring 
increased dosing
Nature of the pain Pain sensations in the 
distribution of the damaged 
neurological structure; i.e. 
pain in the area served 
by the damaged nerve or 
neurological structure. The 
area of neuropathy may show 
hyperalgesia and/or allodynia
The original pain may be well 
controlled or exacerbated. OIH 
pain may be much more diffuse 
and cannot be explained by the 
neuro-anatomical distribution, 
i.e. in dermatomes. In the area of 
OIH there may be hyperalgesia or 
allodynia
Pain sensitivity is unaltered; 
the original pain may still be 
present or be well controlled
How fast can 
this phenomenon 
develop?
Usually a couple of weeks or 
months after nerve damage
May develop rapidly, within 
hours or days
Usually develops slowly in 
weeks or months
Benefits of 
increasing the opiod 
dose 
With increasing doses of 
opioids, there is usually an 
increase in adverse effects but 
no improvement in analgesia 
Single/acute dose may be 
experienced as beneficial, 
although increasing the total dose 
of opioids does not usually result 
in pain improvement. Patients can 
usually state that, for example, 
doubling the dose of opioids did 
not improve the pain and if 
anything made the pain worse
Increasing the dose 
has a beneficial effect 
for a longer time, i.e. 
patients start on a dose of 
fentanyl 25 mg/ hour and after 
a couple of weeks this increases to 
37.5 mg/hour, still without 
adverse effect and with 
adequate control of pain
Quality of pain Usually burning, lacerating or 
stabbing
Usually different from the original 
pain. May have a character of 
sensitivity to touch or slightly 
painful stimuli
Unaltered in comparison to 
the original pain condition
Pain sensitivity Increased Increased Unchanged
Pain threshold Decreased Decreased Unchanged
Opioid adverse 
effects
Usual opioid adverse effects, 
indicating overdosing
May be accompanied by other 
symptoms of neurotoxicity: 
agitation, delirium, multifocal 
myoclonus, seizures
Usual opioid adverse effects, 
indicating overdosing
Initial response to 
opioids
Pain improvement up to 
a certain level; further increase 
in the opioid dose does not 
result in better analgesia
The pain may initially respond 
to opioids; however, it may also 
immediately get worse after 
starting opioids
Pain usually responds well to 
opioids
Effect of dose 
reduction
The pain will increase The pain will decrease The pain will increase
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doses of naloxone and naltrexone [23]. Ultra-low 
doses of naloxone and naltrexone are found to be 
effective when administered together with opio-
ids [24–26]. New combination preparations are cur-
rently undergoing clinical trials.
Opioid tolerance can be treated with increasing 
doses of opioids, providing the speed of devel-
opment of the tolerance is not too high and the 
patient’s prognosis is short. However, as cancer 
patients tend to live longer, this approach will no 
longer be sufficient in many cases. Switching to other 
opioids may counteract opioid tolerance, at least for 
a while [27–29]. However, evidence for this procedure 
is still very scarce [27]. Another approach may be 
the combining of opioids [30]. However, because of 
an outdated paradigm that “all opioids are similar 
as they act on the mu-opioid receptors”, we have 
never seriously considered this possibility and the 
data are absent. 
One last remarkable, and still unexplained feature 
in this case was complete lack of constipation despite 
very high doses of morphine. Later, after swapping 
him to methadone, he became constipated. We do 
not know the true meaning of this fact. It is possible 
that some opioid receptors do not accept morphine 
but are able to interact with other opioids.
Conclusion
Our patient suffered from severe pain most prob-
ably because of OIH. There were insufficient argu-
ments to label this pain as neuropathic. Elements of 
opioid tolerance were also present. OIH and opioid 
tolerance share some characteristics. However, a re-
duction of the opioid dose may be a factor that will 
differentiate between them. The patient was success-
fully treated with morphine switched to methadone 
and the addition of diclofenac. 
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